All In Biotech

Drug Trial Radar · NCT06215820

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

A Multi-Center, Randomized, Double-Blind, Placebo- (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Last checked: Nov 20, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

410

Actual

Start

Dec 29, 2023

Primary completion

Aug 24, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
Viatris Specialty LLCIndustry
Sponsor type
Industry
Collaborators
Mylan Specialty, LP
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after bunionectomy.

Conditions

  • Acute Pain
  • Post Operative Pain
  • Pain

Interventions

  • MR-107A-02Drug

    tablet

  • TramadolDrug

    over-encapsulated tablet

  • PlaceboDrug

    over-encapsulated tablet and/or tablet

  • BunionectomyProcedure

    Primary unilateral bunionectomy with first metatarsal osteotomy under regional anesthesia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summed Pain Intensity Difference (SPID) for MR-107A-02 versus placebo.Time frame: 48 hours after randomization

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator site 114

    Sheffield, Alabama

  • Investigator site 115

    Phoenix, Arizona

  • Investigator site 103

    Anaheim, California

  • Investigator site 110

    Riverside, California

  • Investigator site 112

    Miami, Florida

  • Investigator site 108

    Tampa, Florida

  • Investigator site 109

    Atlanta, Georgia

  • Investigator site 104

    O'Fallon, Illinois

  • Investigator site 102

    Pasadena, Maryland

  • Investigator site 113

    Bellaire, Texas

  • Investigator site 107

    Carrollton, Texas

  • Investigator site 106

    Houston, Texas

  • Investigator site 111

    McAllen, Texas

  • Investigator site 105

    San Antonio, Texas

  • Investigator site 101

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.